Stock Scorer

NRC Health (NRC)

NRC Health reported revenue of 35.4M USD for the quarter ending 30 June 2026, up 4.0% from 34M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 35.4M +4.0%
Operating Income Q2 '26 · ending 30 June 2026 -3.2M -303.9%
Net Income Q2 '26 · ending 30 June 2026 -3.3M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 1.4M —
Free Cash Flow Q2 '26 · ending 30 June 2026 62K —
Shares Outstanding Q2 '26 · ending 30 June 2026 22M -4.2%
EPS Q2 '26 · ending 30 June 2026 49.74 +6444.7%

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 137.4M22.6M11.6M15.7M
20242024-12-31 143.1M35.2M24.8M19.2M
20232023-12-31 148.6M40M31M22.3M
20222022-12-31 151.6M46.5M31.8M26.4M
20212021-12-31 148M50.3M37.5M40.8M
20202020-12-31 133.3M42.7M37.3M36.7M
20192019-12-31 128M43M32.4M36.3M
20182018-12-31 119.7M35.3M30M33.9M
20172017-12-31 117.6M34.2M22.9M23.5M
20162016-12-31 109.4M31.2M20.5M22.9M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3035.4M
Q1 '262026-03-3134.8M
Q4 '252025-12-3135.2M
Q3 '252025-09-3034.6M
Q2 '252025-06-3034M
Q1 '252025-03-3133.6M
Q4 '242024-12-3136.9M
Q3 '242024-09-3035.8M
Q2 '242024-06-3035M
Q1 '242024-03-3135.3M
Q4 '232023-12-3138M
Q3 '232023-09-3037.9M
Q2 '232023-06-3036.2M
Q1 '232023-03-3136.5M
Q4 '222022-12-3138.1M
Q3 '222022-09-3037.7M
Q2 '222022-06-3037.3M
Q1 '222022-03-3138.4M
Q4 '212021-12-3138.3M
Q3 '212021-09-3037.8M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-3.2M
Q1 '262026-03-315.6M
Q4 '252025-12-314.7M
Q3 '252025-09-307.7M
Q2 '252025-06-301.6M
Q1 '252025-03-318.6M
Q4 '242024-12-319.6M
Q3 '242024-09-308M
Q2 '242024-06-308.9M
Q1 '242024-03-318.8M
Q4 '232023-12-3111.7M
Q3 '232023-09-3010M
Q2 '232023-06-309.4M
Q1 '232023-03-319M
Q4 '222022-12-3112.2M
Q3 '222022-09-3011.1M
Q2 '222022-06-3011.5M
Q1 '222022-03-3111.7M
Q4 '212021-12-3112.9M
Q3 '212021-09-3013.1M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-3.3M
Q1 '262026-03-313.2M
Q4 '252025-12-311.8M
Q3 '252025-09-304.1M
Q2 '252025-06-30-106K
Q1 '252025-03-315.8M
Q4 '242024-12-316.6M
Q3 '242024-09-305.7M
Q2 '242024-06-306.2M
Q1 '242024-03-316.4M
Q4 '232023-12-318.9M
Q3 '232023-09-307.9M
Q2 '232023-06-307.3M
Q1 '232023-03-317M
Q4 '222022-12-316.6M
Q3 '222022-09-308.3M
Q2 '222022-06-308.3M
Q1 '222022-03-318.5M
Q4 '212021-12-319.6M
Q3 '212021-09-309.7M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-301.4M
Q1 '262026-03-317.2M
Q4 '252025-12-317.2M
Q3 '252025-09-3013.8M
Q2 '252025-06-30-1.1M
Q1 '252025-03-316.6M
Q4 '242024-12-316.4M
Q3 '242024-09-309.4M
Q2 '242024-06-306.8M
Q1 '242024-03-3112M
Q4 '232023-12-3111.7M
Q3 '232023-09-309.8M
Q2 '232023-06-308.8M
Q1 '232023-03-317.8M
Q4 '222022-12-318.1M
Q3 '222022-09-3010.1M
Q2 '222022-06-309.8M
Q1 '222022-03-318.3M
Q4 '212021-12-3112.1M
Q3 '212021-09-308.7M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-3062K
Q1 '262026-03-315.3M
Q4 '252025-12-316.1M
Q3 '252025-09-3010.2M
Q2 '252025-06-30-4.1M
Q1 '252025-03-313.7M
Q4 '242024-12-311.9M
Q3 '242024-09-307.8M
Q2 '242024-06-301.5M
Q1 '242024-03-317.9M
Q4 '232023-12-317.9M
Q3 '232023-09-305.3M
Q2 '232023-06-304.5M
Q1 '232023-03-314.6M
Q4 '222022-12-316.1M
Q3 '222022-09-306.1M
Q2 '222022-06-308.5M
Q1 '222022-03-315.7M
Q4 '212021-12-3110.4M
Q3 '212021-09-307.7M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3022M
Q1 '262026-03-3121.9M
Q3 '252025-09-3022.1M
Q2 '252025-06-3022.7M
Q1 '252025-03-3123M
Q3 '242024-09-3023.7M
Q2 '242024-06-3023.9M
Q1 '242024-03-3124M
Q3 '232023-09-3024.7M
Q2 '232023-06-3024.7M
Q1 '232023-03-3124.7M
Q3 '222022-09-3024.8M
Q2 '222022-06-3025.2M
Q1 '222022-03-3125.4M
Q3 '212021-09-3025.6M
Q2 '212021-06-3025.6M
Q1 '212021-03-3125.7M
Q3 '202020-09-3025.7M
Q2 '202020-06-3025.7M
Q1 '202020-03-3125.7M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-3049.74
Q1 '262026-03-3149.88
Q4 '252025-12-3149.99
Q3 '252025-09-300.70
Q2 '252025-06-300.76
Q1 '252025-03-311.03
Q4 '242024-12-311.05
Q3 '242024-09-301.13
Q2 '242024-06-301.21
Q1 '242024-03-311.24
Q4 '232023-12-311.25
Q3 '232023-09-301.16
Q2 '232023-06-301.17
Q1 '232023-03-311.21
Q4 '222022-12-311.27
Q3 '222022-09-301.38
Q2 '222022-06-301.43
Q1 '222022-03-311.45
Q4 '212021-12-311.47
Q3 '212021-09-301.41